Year: 2021
Type: article
Abstract: Populations with COPD demonstrate higher survival in overweight and obese compared with normal weight; the “obesity paradox”. Relationships in less-severe COPD are unclear, as is the impact of cardiovascular risk, and few studies include individuals at extremes of obesity. We examined the relationship between body mass index (BMI; defined as underweight: <20 kg·m−2, normal: 20–25 kg·m−2, overweight: 25– <30 kg·m−2, obese class I: 30– <35 kg·m−2, class II: 35– <40 kg·m−2and class III: ≥40 kg·m−2), morbidity, and mortality in the SUMMIT trial population (n=16 485), characterised by moderate COPD and heightened cardiovascular risk with a substantial proportion with class III obesity. The association between BMI category and time to event was modelledviaproportional hazards (reference normal weight) adjusted for demographics and cardiorespiratory disease. Consistent with the paradox, underweight individuals demonstrated higher mortality (hazard ratio (HR) 1.31 (95% CI 1.04–1.64)), with lower mortality among overweight (HR 0.62 (95% CI 0.52–0.73)) and obese class I (HR 0.75 (95% CI 0.62–0.90)). However, mortality increased in obese class III (HR 1.36 (95% CI 1.00–1.86)). Death was primarily attributable to cardiovascular causes. Within a large, multinational cohort with moderate COPD and increased cardiovascular risk, the phenomenon of reduced mortality with obesity did not persist at BMI >40 kg·m−2, suggesting that obesity may not remain protective at the extremes in this population.
Source: ERJ Open Research
Institutions: Johns Hopkins University, Johns Hopkins Medicine, Johns Hopkins Hospital, GlaxoSmithKline (United Kingdom), GlaxoSmithKline Research & Development Limited (United Kingdom), Wayne State University, University of Liverpool, Aintree University Hospital, Brigham and Women's Hospital, Harvard University, GlaxoSmithKline (United States), Weill Cornell Medicine, University of Edinburgh, Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Baylor College of Medicine
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $808
Funders: GlaxoSmithKline, British Heart Foundation
Awards: G2574353342, G3227981690
OpenAlex ID: W3177274233
